Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy

Table 2 Outcomes after portal vein embolization with or without transarterial chemoembolization and before hepatectomy

Variable	siTP group (n = 13)	seTP group (n = 17)	PVE-only group (n = 21)	P value
FLR (%) (before hepatectomy)	45.9 ± 4.2	43.3 ± 6.6	43.0 ± 4.7	0.262
Interval from TACE/PVE to hepatectomy	16.2 ± 2.7	37.9 ± 6.5	35.4 ± 10.6	< 0.001
KGR (%)	21.1 ± 5.9	7.6 ± 2.9	6.8 ± 3.6	< 0.001
Tumor size reduction, n (%)	13 (100)	13 (76)	2 (10)	< 0.001
Complications, n (%)				0.875
Abdominal pain	6 (46)	9 (53)	3 (14)
Fever	7 (54)	8 (47)	3 (14)
Nausea	2 (15)	4 (24)	2 (10)
Acute pulmonary infarction	0	1 (6)	0

FLR: Future liver remnant; TACE: Transarterial chemoembolization; PVE: Portal vein embolization; KGR: Kinetic growth rate; seTP: Sequential TACE + PVE; siTP: Simultaneous TACE + PVE.